Analysts Set Expectations for RCKT Q2 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings estimates for Rocket Pharmaceuticals in a report released on Thursday, February 27th. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for Rocket Pharmaceuticals' Q4 2025 earnings at ($0.50) EPS.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06.

Several other research analysts have also commented on RCKT. The Goldman Sachs Group cut their price objective on Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating on the stock in a research report on Monday. Canaccord Genuity Group reduced their price target on Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating on the stock in a research report on Monday. Wedbush initiated coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They issued an "outperform" rating and a $32.00 price objective for the company. Leerink Partners dropped their price objective on shares of Rocket Pharmaceuticals from $46.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, November 19th. Finally, Scotiabank upped their target price on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $42.30.

Remove Ads

Rocket Pharmaceuticals Trading Down 2.4 %

RCKT stock traded down $0.22 during midday trading on Monday, reaching $8.99. 1,557,491 shares of the company's stock traded hands, compared to its average volume of 1,451,795. The business has a 50-day moving average price of $10.73 and a two-hundred day moving average price of $14.48. Rocket Pharmaceuticals has a fifty-two week low of $8.25 and a fifty-two week high of $28.73. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The company has a market capitalization of $819.50 million, a P/E ratio of -3.27 and a beta of 0.98.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Covestor Ltd raised its position in shares of Rocket Pharmaceuticals by 33,166.7% during the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 1,990 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Rocket Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 582 shares during the last quarter. Signaturefd LLC raised its holdings in shares of Rocket Pharmaceuticals by 319.8% during the fourth quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 3,745 shares during the period. Harbour Investments Inc. lifted its position in shares of Rocket Pharmaceuticals by 51.9% in the 4th quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after buying an additional 1,840 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Rocket Pharmaceuticals by 159.6% in the 4th quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after buying an additional 3,366 shares during the period. Institutional investors own 98.39% of the company's stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.